An antisense strategy for inhibition of human melanoma growth targets the growth factor pleiotrophin

K Satyamoorthy1, M Oka, M Herlyn

  • 1The Wistar Institute, Philadelphia 19104, USA.

Pigment Cell Research
|October 21, 2000
PubMed

Insights

Melanoma cells survive without growth factors by producing pleiotrophin (PTN). Inhibiting PTN with antisense (AS) PTN vectors significantly reduced melanoma growth in 3D cultures and in vivo.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Metastatic melanomas exhibit enhanced survival in growth-factor-depleted environments, unlike normal melanocytes.
  • Melanoma cell survival is attributed to autocrine growth stimulation via self-produced growth factors.
  • Pleiotrophin (PTN) is identified as a key heparin-binding autocrine growth factor for melanoma cells.

Discussion:

  • A replication-deficient adenovirus expressing antisense (AS) PTN was developed to inhibit PTN production.
  • AS-PTN vector efficiently inhibited PTN protein synthesis in melanoma cells.
  • Melanoma cell growth inhibition was observed in 3D soft agar but not in monolayer cultures, highlighting the role of cell-matrix interactions.

Key Insights:

  • Down-regulation of PTN correlated with decreased cyclin E and increased p21WAF1/Cip1, affecting cell-cycle regulation.
  • AS-PTN vector demonstrated efficacy in delaying tumor growth in vivo.
  • PTN is crucial for the three-dimensional growth of melanoma cells.

Outlook:

  • Future melanoma antagonist assessments should include 3D matrices, not solely monolayers.
  • Targeting PTN represents a potential therapeutic strategy for melanoma.
  • Understanding cell-matrix interactions is vital for developing effective melanoma treatments.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...